Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired
Shidlovski

Reata Pharmaceutics quickly rose 0.5% after disclosing that the HSR waiting period for its planned sale to Biogen (NASDAQ:BIIB) expired.
The waiting period expired on Monday, according to an 8-K filing.

Biogen Inc. (BIIB) agreed to buy Reata Pharma (NASDAQ:RETA) for $172.50 per share in cash, or an enterprise value of about $7.3 billion, for the rare disease drug maker in late July.



More on Reata Pharmaceuticals

Seeking Alphaâs Quant Rating on Reata Pharmaceuticals
Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors
Sanofi was mystery suitor in Reata Pharma bidding war - report
Biggest stock movers today: Reata Pharmaceuticals, Enphase Energy, Roku and more
Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B
TD Cowen starts Reata at outperform, cites sales potential of ataxia drug